INDRAMEDCOIndraprastha Medical Corporation Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive medicine, and sleep medicine. Indraprastha Medical Corporation Limited was founded in 1983 and is based in New Delhi, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Overall evidence is weak (AlgoScore 38/100)
- • Profit growth: 1.8% YoY
- • PEG ratio: 9.92
- • RSI: 41
- • MACD: bearish
- • Double Top bearish signal (setup quality 64%)
Bull case
- • ROE: 27.5%
- • ROCE: 28.7%
- • Debt/Equity: 0.05
- • Liquidity: ₹6.4 cr avg turnover
Bear case
- • Profit growth: 1.8% YoY
- • PEG ratio: 9.92
- • RSI: 41
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Profit growth: 1.8% YoY
- • PEG ratio: 9.92
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹8.82). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.